Skip Nav Destination
Close Modal
Search Results for
Clinical applications of GLP-1 based therapies
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Journal
Article Type
Topics
Subjects
Issue Section
Date
Availability
1-20 of 654 Search Results for
Clinical applications of GLP-1 based therapies
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
1
Sort by
Meeting Abstracts
Journal:
Diabetes
Diabetes 2023;72(Supplement_1):569-P
Published: 20 June 2023
.... Practicing Clinicians Exchange (PCE) developed an educational program on GLP-1 RAs followed by virtual patient simulations to address educational and clinical application needs. Methods: Following a series of live education, 2 virtual patient simulations were released in October 2022. NPs and PAs received...
Journal Articles
John M. Dennis, Beverley M. Shields, Anita V. Hill, Bridget A. Knight, Timothy J. McDonald, Lauren R. Rodgers, Michael N. Weedon, William E. Henley, Naveed Sattar, Rury R. Holman, Ewan R. Pearson, Andrew T. Hattersley, Angus G. Jones
Journal:
Diabetes Care
Diabetes Care 2018;41(4):705–712
Published: 31 January 2018
... in a prospective study and validated in real-world data and provide a starting point for the application of a precision diabetes approach with DPP-4 inhibitor therapy. Figure 3 GLP-1 receptor agonists: associations between markers of insulin resistance and HbA1c response at 6 months. Circles...
Includes: Supplementary data
Meeting Abstracts
Journal:
Diabetes
Diabetes 2022;71(Supplement_1):14-LB
Published: 01 June 2022
... of medication management (anti-hypertensives, SGLT2 inhibitors/GLP1 agonists) and specialist referral was tracked. An interim analysis was performed for 1) Assessing comparability between RWE and a published clinical validation cohort based on KidneyIntelX risk score distribution; 2) Determining if necessary...
Book Chapter
Published: 2024
10.2337/9781580408387.ch04
...., A1C >10% [>86 mmol/mol] or blood glucose ≥300 mg/dL [≥16.7 mmol/L]). E 9.23 In adults with type 2 diabetes, a GLP-1 RA, including a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA, is preferred to insulin ( Fig. 4.2 ). A 9.24 If insulin is used, combination therapy...
Book Chapter
.... The American College of Clinical Endocrinology positions SGLT2 inhibitors and/or GLP-1 as the preferred second-line therapy, after metformin, for most patients with type 2 diabetes who can afford these agents. The American Diabetes Association recommends SGLT2 inhibitors as the preferred second-line agent...
Book
Book Chapter
Published: 2017
10.2337/9781580406482.ch06
... available for treatment of diabetes in the U.S. and six specifically affect postprandial hyperglycemia: sulfonylureas, meglitinides, α-glucosidase inhibitors, glucagon-like peptide-1 (GLP-1) agonists, dipeptidyl peptidase-4 inhibitors, and insulin. 55 Three classes of medications, the GLP-1...
Journal Articles
Journal:
Diabetes
Diabetes 2024;74(1):1–3
Published: 20 December 2024
... to the understanding and application of GLP-1–based therapies. The first GLP-1 receptor agonist reached clinical use in 2005. It was a derivative of exendin-4, or exenatide, which is an injectable peptide that demonstrated reliable glucose-lowering properties and modest reductions in body weight ( 18 ); the latter...
Journal Articles
Journal:
Diabetes Care
Diabetes Care 2025;48(1):3–5
Published: 20 December 2024
... and application of GLP-1–based therapies. The first GLP-1 receptor agonist reached clinical use in 2005. It was a derivative of exendin-4, or exenatide, which is an injectable peptide that demonstrated reliable glucose-lowering properties and modest reductions in body weight ( 18 ); the latter finding...
Book Chapter
Published: 2024
10.2337/9781580408387.ch17
... 10.3, reproduced from that decision pathway, outlines the approach to risk reduction with SGLT2 inhibitor or GLP-1 receptor agonist therapy in conjunction with other traditional, guideline-based preventive medical therapies for blood pressure, lipids, and glycemia and antiplatelet therapy. Figure 17.3...
Book Chapter
... signals. Further studies are needed to assess whether promising classes of agents, such as GLP-1 agonists and SLGT2 inhibitors, will provide important long-term benefits in terms of cardiac and renal protection in those with type 1 diabetes. Use of adjunctive agents (particularly off-label use...
Book Chapter
Published: 2017
10.2337/9781580406482.ch07
... experiencing hypoglycemia. Information on treatment of hypoglycemia is explored in greater detail in Chapter 13: Nutrition Therapy for Diabetes: Hypoglycemia and Sick Days . Table 7.1 Weight Effects of Glucose-Lowering Medications Medication Class Weight Effects GLP-1 analogs ↓ Pramlintide...
Journal Articles
Takuya Haraguchi, Yuji Yamazaki, Hitoshi Kuwata, Ryota Usui, Yoshiyuki Hamamoto, Yutaka Seino, Daisuke Yabe, Yuichiro Yamada
Journal:
Diabetes
Diabetes 2024;73(12):2078–2083
Published: 28 August 2024
...-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs) and dipeptidyl peptidase 4 inhibitors (DPP-4is). We aimed to determine whether the amount of insulin secretion induced by pharmacologic glucagon stimulation is reduced under these incretin-based therapies, because they both act through GLP-1...
Journal Articles
Journal:
Diabetes
Diabetes 2024;73(10):1566–1582
Published: 08 July 2024
... – 158 7.
Rorsman P , Huising MO . The somatostatin-secreting pancreatic δ-cell in health and disease . Nat Rev Endocrinol 2018 ; 14 : 404 – 414 8.
Prasad-Reddy L , Isaacs D . A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes...
Book Chapter
Published: 2017
10.2337/9781580406482.ch08
... was published in 2004 and, at that time, approximately one-half of youth with type 2 diabetes treated with medication received insulin and one-half oral agents, most commonly metformin. 55 A clinical trial assessing the use of liraglutide, a glucagon-like peptide-1 (GLP-1) drug, in pediatric...
Journal Articles
Journal:
Diabetes Care
Diabetes Care dc242575
Published: 14 January 2025
... microdosing may provide a safer and more consistent alternative, allowing for dose adjustments without signi cant disruptions in therapy. The following scenarios should be considered for clinical application of microdosing. Transitioning between GLP-1RA. Microdosing can help patients transition to a new GLP...
Journal Articles
Journal:
Diabetes Care
Diabetes Care 2021;44(6):1344–1352
Published: 19 April 2021
... for potential effects of GLP1-RA beyond glucose control. Indeed, based on recent clinical trials evidence, several GLP-1RA (liraglutide, semaglutide, and dulaglutide) have been granted a U.S. Food and Drug Administration indication for major cardiovascular risk prevention in patients with T2D and cardiovascular...
Journal Articles
Journal:
Diabetes Spectrum
Diabetes Spectr 2024;37(4):325–334
Published: 15 November 2024
... by both the American Association of Clinical Endocrinology ( 5 ) and the European Association for the Study of Obesity ( 6 ). Figure 1 Current drug development in obesity based on NRHs. GLP-1, GIP, glucagon, amylin, and PYY are nutrient-stimulated hormones that suppress appetite, and examples...
Journal Articles
Joshua J. Neumiller, Mandeep Bajaj, Raveendhara R. Bannuru, Rozalina G. McCoy, Elizabeth J. Pekas, Alissa R. Segal, Nuha A. ElSayed
Journal:
Diabetes Care
Diabetes Care 2025;48(2):177–181
Published: 02 December 2024
... to the clinic with compounded GLP-1 RA and dual GIP/GLP-1 RA dosage forms not available for the FDA-approved products (e.g., oral and sublingual products) and even compounded incretin therapies not yet approved by the FDA (e.g., retatrutide). The increasing availability of such products poses important concerns...
Journal Articles
Journal:
Diabetes Care
Diabetes Care 2021;44(6):1443–1446
Published: 18 June 2021
... that 33% of patients with diabetes would be eligible for an SGLT2i or GLP-1 RA based on cardiorenal comorbidities, 13% of patients met criteria for an SGLT2i based on heart failure or albuminuric chronic kidney disease (CKD), and 18% of patients met criteria for either agent based on atherosclerotic...
1